Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, Zhejiang, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, Zhejiang, China.
Signal Transduct Target Ther. 2021 Feb 20;6(1):72. doi: 10.1038/s41392-020-00449-4.
Despite great success in cancer immunotherapy, immune checkpoint-targeting drugs are not the most popular weapon in the armory of cancer therapy. Accumulating evidence suggests that the tumor immune microenvironment plays a critical role in anti-cancer immunity, which may result in immune checkpoint blockade therapy being ineffective, in addition to other novel immunotherapies in cancer patients. In the present review, we discuss the deficiencies of current cancer immunotherapies. More importantly, we highlight the critical role of tumor immune microenvironment regulators in tumor immune surveillance, immunological evasion, and the potential for their further translation into clinical practice. Based on their general targetability in clinical therapy, we believe that tumor immune microenvironment regulators are promising cancer immunotherapeutic targets. Targeting the tumor immune microenvironment, alone or in combination with immune checkpoint-targeting drugs, might benefit cancer patients in the future.
尽管癌症免疫疗法取得了巨大成功，但免疫检查点靶向药物并不是癌症治疗武器库中最受欢迎的药物。越来越多的证据表明，肿瘤免疫微环境在抗肿瘤免疫中起着关键作用，这可能导致免疫检查点阻断治疗无效，此外，癌症患者还需要其他新型免疫疗法。在本综述中，我们讨论了当前癌症免疫疗法的不足。更重要的是，我们强调了肿瘤免疫微环境调节剂在肿瘤免疫监视、免疫逃逸中的关键作用，并探讨了它们进一步转化为临床实践的潜力。基于它们在临床治疗中的普遍靶向性，我们认为肿瘤免疫微环境调节剂是很有前途的癌症免疫治疗靶点。针对肿瘤免疫微环境，单独或与免疫检查点靶向药物联合使用，可能在未来使癌症患者受益。
Zotero 插件
